Emerging drugs for Guillain-Barré syndromeEmerging treatments for noise-induced hearing lossEmerging drugs for uveitisEmerging drugs for the treatment of anxietyThe immediate future for the medical treatment of atrial fibrillationEmerging drugs in peripheral arterial diseaseEmerging drugs for the treatment of tobacco dependence: 2014 updateEmerging adenosine receptor agonistsDevelopments in the treatment of visceral leishmaniasisPotential therapeutic targets for neurokinin-1 receptor antagonistsTreatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitorsEmerging therapy for endometriosisEmerging drugs for sarcopenia: age-related muscle wastingEmerging targeted therapies for glioma.Promising therapies for treatment of nonalcoholic steatohepatitis.Emerging drugs for chronic lymphocytic leukaemia.New targets, new drugs for metastatic bone pain: a new philosophy.Emerging pharmacotherapy of tinnitus.Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Emerging drugs for moderate-to-severe psoriasis.Emerging therapies in multiple sclerosis.Pharmacologic therapy for diabetic retinopathy.Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration.Current and future pharmacological intervention for diabetic retinopathy.Synthetic polymer systems in drug development.Photodynamic therapy systems and applications.Advances in ischemic stroke treatment: neuroprotective and combination therapies.Emerging pharmacotherapies for diabetic macular edema.Emerging anticoagulant and thrombolytic drugs.Emerging drugs for diabetic retinopathy.Emerging drugs for myelofibrosis.Emerging drugs for immune thrombocytopenia (ITP).Emerging PEGylated drugs.Emerging drugs for chronic myeloid leukemia.Current and emerging drug treatments for binge eating disorder.Emerging Bcl-2 inhibitors for the treatment of cancer.Emerging gonadotropin-releasing hormone agonists.Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaAnti-endothelin drugs in solid tumors.Emerging drugs for varicella-zoster virus infections.
P1433
Q22241376-39CB0A6B-B490-4F5E-9F05-83CC5163E0ACQ24630807-26E6F75E-BC7F-419E-ACA5-A215E94A3922Q24630848-4108822B-E7C3-49E1-ABEB-9920396FC689Q28083141-7C5FAB48-D99E-4746-A4AC-F414EB750AE3Q28182304-9E764258-B6D6-44AD-B983-981C64A1FF1CQ28195408-4941C02D-951E-4B05-87F1-0F16AD7D1C1FQ28236453-FE64B1D3-1006-4487-BF9C-55225E0754B4Q28249111-E56F4174-4B8A-44CE-9380-DE9D12C755A4Q28256441-C93CA8AC-3DB4-4434-A3B0-FA622530F8FEQ28262693-287C7445-6639-4096-BE03-D387AC9F764BQ28262703-ED6E5B0C-3BEB-4F36-A4FD-E4CB44646AF1Q28262987-71F39676-B84D-4B3D-A93B-8996D3542022Q28295716-F57050DF-4B72-43E2-ADBE-C7292E7406B3Q30241853-298EDA28-0CF3-4A9D-8210-26908D72C4FDQ30248578-165E4FEE-F179-4342-8842-851BBAEC95EFQ30353154-BD0207C9-E8C7-456E-BB88-050961DD1200Q30403253-2050A22B-EE24-43F8-830D-52A85C6AE64CQ30478378-2C66ED65-9F4B-47FB-9482-7A9F3CB91B61Q30595943-10E8F4BD-9466-4712-B62B-F8E1836BE5D5Q30984470-C11DACA0-EF4C-4B4D-A1DC-AD5D0A819628Q31015100-47625D8C-F7EC-421C-8464-F2E43DDC2653Q33194915-1D4F45C4-0C35-4984-B532-298BC27BF232Q33212693-406C42A5-1A8F-488B-93BE-B30B72B7C06EQ33216425-B4EE0D9A-2917-43E0-A6E2-1E5CB5BABFC6Q33218263-DEB53A88-7933-4319-8A44-203B741F09BEQ33218266-A3CD064B-ACA3-48B7-8B20-77F556C0B8A0Q33278117-63F087E5-F274-42EB-8A5C-D5B1A6D0876DQ33304852-4B3CF733-C867-45E2-B38D-7EF8144F9B64Q33367019-9E7A713A-107E-4FDC-9ABC-94259CD26A84Q33388498-6044DCF5-20EC-441D-831F-20EFE80EE05CQ33404574-D8D05877-5ABC-4EF9-81DF-16347A925941Q33439789-A0CCD575-3D6A-429D-8A6F-872A2AC04048Q33447691-857F268E-01BC-441F-96B1-7210122A4FCDQ33536762-7FDDC7A4-F91A-4EF3-9043-EBEDA33F43EEQ33634698-0EBC0EAE-A464-410F-A1DA-4B93C11C77BDQ33682689-CB93346A-5326-4E23-A650-E7728C275ACAQ33796122-29F82C2E-2E30-4274-A15D-B861637132DFQ34004131-8D22F75B-6483-46B0-8B78-A4650062F69AQ34021011-3D039EA0-C9DC-401D-9181-EE7ACA7FE785Q34027426-8229B146-04A1-411F-9446-682D53A34BF3
P1433
description
Medical journal
@en
Medical journal
@en-gb
Revue médicale
@fr
Wissenschaftliche Fachzeitschrift
@de
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Informa
@nl
वैज्ञानिक पत्रिका
@hi
name
Expert Opinion on Emerging Drugs
@ast
Expert Opinion on Emerging Drugs
@da
Expert Opinion on Emerging Drugs
@de
Expert Opinion on Emerging Drugs
@en
Expert Opinion on Emerging Drugs
@en-ca
Expert Opinion on Emerging Drugs
@en-gb
Expert Opinion on Emerging Drugs
@es
Expert Opinion on Emerging Drugs
@fi
Expert Opinion on Emerging Drugs
@fr
Expert Opinion on Emerging Drugs
@it
type
label
Expert Opinion on Emerging Drugs
@ast
Expert Opinion on Emerging Drugs
@da
Expert Opinion on Emerging Drugs
@de
Expert Opinion on Emerging Drugs
@en
Expert Opinion on Emerging Drugs
@en-ca
Expert Opinion on Emerging Drugs
@en-gb
Expert Opinion on Emerging Drugs
@es
Expert Opinion on Emerging Drugs
@fi
Expert Opinion on Emerging Drugs
@fr
Expert Opinion on Emerging Drugs
@it
altLabel
Exp. Opin. Emerg. Drugs
@de
Exp. Opin. Emerg. Drugs
@en
Exp. Opin. Emerg. Drugs
@en-gb
Exp. Opin. Emerg. Drugs
@fr
prefLabel
Expert Opinion on Emerging Drugs
@ast
Expert Opinion on Emerging Drugs
@da
Expert Opinion on Emerging Drugs
@de
Expert Opinion on Emerging Drugs
@en
Expert Opinion on Emerging Drugs
@en-ca
Expert Opinion on Emerging Drugs
@en-gb
Expert Opinion on Emerging Drugs
@es
Expert Opinion on Emerging Drugs
@fi
Expert Opinion on Emerging Drugs
@fr
Expert Opinion on Emerging Drugs
@it
P236
P3181
P1055
P1058
P123
P1277
P1476
Expert Opinion on Emerging Drugs
@en
P236
P3181
P407
P571
1996-01-01T00:00:00Z